PLK1 and mucinous ovarian cancer: We explored the effects of PLK1 inhibitors in mucinous ovarian cancer cell lines, either as single agents or in combination with the chemotherapeutic drugs used as standard therapy for treatment of mEOC, and found that the combination of onvansertib (a PLK1 inhibitor) and paclitaxel was extremely active both in vitro and in vivo.